CJ
MDGL icon

Caitlin John’s Madrigal Pharmaceuticals MDGL Stock Holding History

Caitlin John’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.05K Hold
2
– – ﹤0.01% 794
2025
Q4 		$1.17K Hold
2
– – ﹤0.01% 778
2025
Q3 		$917 Buy
+2
New +$746 ﹤0.01% 775

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Caitlin John's MDGL Position: Q1 2026 in Review

Caitlin John held its Madrigal Pharmaceuticals (MDGL) position steady in Q1 2026 at 2 shares worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #794.

Caitlin John first reported a position in MDGL in Q3 2025 and has held it in 3 quarters since. The position peaked at $1.17K in Q4 2025. 378 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Caitlin John held 2 shares of Madrigal Pharmaceuticals worth $1.05K as of Q1 2026.
  • Caitlin John left its Madrigal Pharmaceuticals share count unchanged in Q1 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Caitlin John's portfolio in Q1 2026, its #794 holding.
  • Caitlin John first reported a position in Madrigal Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Caitlin John's Madrigal Pharmaceuticals position peaked at $1.17K in Q4 2025.
  • 378 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Caitlin John's 13F filing for Q1 2026, filed 13 May 2026.